Kraft Heinz, Unilever, Hain Celestial and Keurig Dr Pepper are separating business units as private equity carve-out deal value rose to $23.72 billion across 145 deals in the first half of 2025, up from $19.37 billion across 127 deals a year earlier. Coca-Cola has committed $10 billion to US plants…
Kraft Heinz, Unilever, Hain Celestial and Keurig Dr Pepper are separating business units, and the moves arrive alongside a sharp rise in private equity carve-out activity in packaged food. Private equity carve-out deal value reached $23.72 billion across 145 deals in the first half of 2025, up from $19.37 billion across 127 deals in the first half of 2024. That is roughly 22 percent more capital spread across about 14 percent more transactions, which means average deal size grew rather than transaction count alone.
Unilever is separating its ice cream business. Hain Celestial is separating its international operations. Keurig Dr Pepper is separating coffee and beverages. Kraft Heinz is splitting units as well. The rationale the companies give is consistent: legacy margin discipline, the practice of funding an entire portfolio from the cash thrown off by mature categories, was limiting capital available to growth brands.
Coca-Cola has moved in the other direction, committing capital into its own manufacturing base instead of dividing the company. Coca-Cola and its bottling partners have committed $10 billion to US infrastructure through 2030. The spending covers bottling plants, production facilities and distribution centers across at least eight states.
The Coca-Cola commitment includes Fairlife plant expansions in Michigan and New York, bottling operations in California, Colorado, Indiana and Alabama, and a distribution center in Florida. Fairlife is the company's dairy brand, and the plant expansions put capital behind a product line that sells on protein content, an attribute that maps directly onto the dietary priorities of the consumers the food industry is now courting.
The investment follows layoffs at Coca-Cola in early 2026, ahead of the announcement. The through-2030 horizon means the capital will be deployed while the input cost picture described below plays out, which gives the commitment a hedging quality: adding domestic capacity while freight, energy and agricultural costs are volatile.
What the separations transfer is less visible than the headline values. Unilever's ice cream unit, Hain Celestial's international operations, Keurig Dr Pepper's coffee and beverages, and the Kraft Heinz units each carry brands, plants, distribution agreements and legacy supply contracts. Buyers, terms and valuations have not been disclosed in the material available, and those details determine whether the transactions free up growth capital or simply move mature assets to owners with a higher tolerance for debt.
Circana data for August show unit demand down 1.7% year over year while dollar sales rose 0.8%. The gap between those two numbers is the story of the current grocery market: volume is contracting, and the only reason revenue is growing at all is price. Fast-moving consumer goods prices rose 26 percent between 2021 and 2025, and nearly 60 percent of shoppers report being more cautious or cutting discretionary spending.
Private label is capturing the shift. Private label sales grew 2.5% in 2024 while national brand sales declined 0.8%. Walmart's Bettergoods line approached $500 million in first-year sales, a figure that shows how quickly a retailer-owned brand can reach scale when consumers are actively shopping for value.
The consequence for mid-market brands is structural rather than cyclical. When shoppers buy fewer items at higher prices, the shelf space devoted to brands without either a price advantage or a defensible functional claim shrinks. That pressure is what makes the GLP-1 repositioning described below attractive to brand owners, and it is also what makes the carve-out math work for private equity buyers who specialize in cost discipline.
GLP-1 drug use now stands at 11% of US adults, up from 3% in 2024. More than 137 million US adults are eligible for GLP-1 use, which means the current 11% figure represents a fraction of the addressable population. Users reduce daily intake by about 700 calories, and households affected by GLP-1 use cut grocery spending by 6%.
The demand signal is concentrated in specific categories. An estimated $73 billion of global food brand value is at risk from GLP-1-driven demand shifts. Confectionery, chocolate and savory snacks account for 53% of that at-risk value while representing 30% of total brand value, a ratio of roughly 1.8 to 1 that marks those categories as disproportionately exposed. GLP-1 use reduces intake of processed foods, sugary drinks, refined grains and savory snacks, which is exactly the list the at-risk value map reflects.
Brand owners have begun reformulating around the shift. Nestlé has positioned Vital Pursuit for GLP-1 users. Conagra has positioned its Healthy Choice line as GLP-1 friendly. Danone has positioned Oikos around muscle retention, addressing a specific clinical concern rather than general satiety.
GLP-1 is a 30-amino-acid incretin hormone released from enteroendocrine L cells in the distal small intestine and colon after a meal. Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4, which is why the therapeutic class required peptide chemistry rather than a small molecule: the approved agents are DPP-4-resistant analogs, often with fatty acid side chains that bind albumin and extend circulation time, or sequences engineered for stability.
The receptor is a class B G protein-coupled receptor that couples to Gs and raises intracellular cAMP. In pancreatic beta cells that signal potentiates glucose-dependent insulin secretion, so insulin release scales with glycemic load rather than firing independently of it. In the hypothalamus, receptor activation drives POMC and CART neurons in the arcuate nucleus while suppressing NPY and AgRP neurons, the circuit that governs hunger and energy balance. Vagal afferents in the gut wall carry satiety signals upward, and the same receptor activation slows gastric emptying, which extends the interval over which a meal produces fullness. Glucagon release falls in a glucose-dependent manner.
That pharmacology explains the category pattern better than any consumer survey can. The behaviors most suppressed are reward-driven and portion-sensitive: snacking between meals, sugary drinks consumed for palatability rather than thirst, and refined grain products whose appeal depends on rapid carbohydrate delivery. Slower gastric emptying and stronger post-meal satiety reduce the number of eating occasions, which is why unit volumes fall faster than dollar sales in the grocery data. For clinicians, the muscle retention question is the practical corollary: weight lost rapidly includes lean mass, and adequate protein intake plus resistance training mitigates it. That is the clinical logic behind positioning a high-protein dairy brand for this population, and it is also why next-generation peptide combinations that pair GLP-1 activity with amylin or GIP signaling are being pursued, since they aim to improve the composition of the weight lost, not just the total.
August food inflation held at 1.3%, a figure that looks benign in isolation and does not survive contact with the producer cost data. Diesel prices rose 77.8% year over year. More than one-third of the month's increase in final-demand goods prices was accounted for by diesel. Grain costs rose 17.7% year over year and oilseed costs rose 15.8%.
Confectionery inputs rose 13.6% on an annual basis and 6.1% in August alone. Raw sugar recorded its largest monthly gain since October 2010. Those numbers land hardest on the exact categories the GLP-1 demand shift is already pressuring, so confectionery and snack manufacturers face volume risk and cost inflation simultaneously, from opposite directions.
The gap between a 1.3% headline and those input figures has two possible resolutions. Manufacturers absorb the difference in margin, or they pass it through later. Because diesel is a cost embedded in every haul, every cold chain and every fertilizer input, and because grain and oilseed feed both food and feed channels, the pass-through is more likely to be delayed than avoided. A 1.3% headline rate is therefore better read as a lagging indicator than as evidence that cost pressure has eased.
The UK Food and Drink Federation projects UK food inflation of 3.9% by December 2026 and 6.4% by July 2027. Those projections place the expected acceleration in the second half of the decade rather than the current quarter, consistent with the lag between input costs and shelf prices visible in the August data.
Longer-term supply risk is concentrated in agriculture. El Niño risk is associated with a forecast 14% drop in global agricultural output over two years, a loss valued at $342.2 billion. Sea surface temperatures are projected at 4°C above average by November 2026. Roughly 26% of global rice production is at risk, and India's monsoon is running 13% below normal. Weather-linked forecasts of this kind carry wide error bars, but the exposure is asymmetric: rice is a staple with limited substitution in the diets that depend on it most.
For procurement teams, sourcing flexibility has been identified as the critical capability. That means qualifying alternative origins and suppliers before disruption rather than during it, and accepting higher carrying costs in exchange for optionality. The same logic applies to any manufacturer whose formulations depend on a small number of agricultural inputs.
For peptide researchers, the consumer data reframes GLP-1 receptor agonists as a durable demand driver rather than a transient trend. An 11% adoption rate against a population of more than 137 million eligible US adults implies substantial headroom, and the $73 billion at-risk brand value figure means the food industry has a financial reason to keep reformulating toward the physiological needs of that population. Demand for high-protein formats creates pull for dairy proteins, protein hydrolysates and bioactive peptides, which sit in the same manufacturing and analytical world as therapeutic peptides.
For clinicians, the practical question is monitoring. A 700-calorie daily reduction produces rapid weight loss, and lean mass preservation requires attention to protein intake and resistance training. Patients on GLP-1 therapy are also changing what they buy, which means dietary counseling has to account for the 6% reduction in household grocery spending and the specific shifts toward less processed food, fewer sugary drinks and fewer refined grains.
For the peptide supply chain, the signals point in two directions. Investment in domestic manufacturing capacity, of the kind Coca-Cola is making, shows how food and beverage companies are responding to freight and tariff exposure, and peptide manufacturers face the same problems through cold-chain logistics and solvent supply. At the same time, rising agricultural costs and 77.8% diesel inflation feed directly into the cost of moving temperature-sensitive materials. Carve-out activity adds a further variable: when a business unit changes ownership, supply agreements, quality specifications and long-term ingredient contracts often get renegotiated, and peptide and protein ingredient suppliers can find their customer relationships reassigned without warning.
The entire cluster of figures comes without a named individual or organization quoted directly. No study, survey or…
Peptides referenced: Amylin, Glucagon, GLP-1.
Related reading: Mississippi Gulf Coast Clinics Add GLP-1 and Peptide Programs, SinCAA: a two-task pretraining model for non-canonical amino acid peptides, Flow matching model NCFlow places unseen non-canonical amino acids, Semaglutide hsCRP cut of 37.8% in SELECT suggests anti-inflammatory role.